Liberty Biopharma System Used in Stroke Study
February 20, 2017, Richmond, British Columbia - Liberty Biopharma Inc. (TSX VENTURE: LTY) (“Liberty Biopharma" or “Company”) is pleased to announce that researchers have used the Company's cellular therapy platform for the processing and isolation of adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes in a live animal stroke model.
The study was conducted in a live rat model to investigate the safety of IV infusion following acute ischemic stroke. Secondary endpoints were the changes in brain infarct volume and neurological function. ADMSC and ADMSC derived exosomes were delivered intravenously without serious adverse outcomes in all rats. Furthermore, those treated after acute ischemic stroke demonstrated markedly reduced brain infarct volume and greater than expected preservation of neurological function compared to controls.
“These results are encouraging. This study further supports the work being done in cell therapy research, specifically from mesenchymal adipose derived cell sources, which demonstrates the potential for cellular therapies to positively influence the environment of damaged or physiologically stressed tissues. Although these results are from animal research, it is exciting to envision a day when physicians may have access to cell therapies which could mitigate the damaging effects of acute neurologic injuries", said Dr. Richard Cook, MD, Chief Medical Officer of Liberty Biopharma.
About Acute Ischemic Stroke Research
Acute ischemic stroke (AIS) is the leading cause of long-term disability and the second leading cause of death worldwide. Currently, there is no universally accepted effective and safe management strategy for all patients with AIS. Thrombolysis with tissue plasminogen activator (tPA) and endovascular intracranial treatment are two treatments for AIS with promising results in specific patient groups. However, strict enrollment criteria and contraindications restrict their use for many potential candidates. Furthermore, tPA appears to be associated with a relatively high incidence of intracranial bleeding complications and poor patency rate in large-vessel occlusion. Endovascular intracranial treatment is only suitable for patients with large-vessel occlusion. Both current intervention options require very specialized clinicians and facilities. Treatment is also very time sensitive. Accordingly, many AIS patients still lack a treatment that is both effective and safe. New approaches for clinicians treating acute ischemic stroke are of particular interest and therapeutic value for those who are not candidates for thrombolysis or endovascular intracranial treatment.
The research paper is published in Vol. 7, issue No. 46 of Oncotarget, and is titled, "Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rats after acute ischemic stroke,”
About Liberty Biopharma Inc.
Liberty Biopharma is a clinical stage biopharmaceutical company developing and commercializing regenerative stem cell technologies and therapeutic solutions for independence and quality of life. Our focus is the significant unmet clinical need in numerous indications including osteoarthritis, wound management, autoimmune diseases and erectile dysfunction.
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", “likely”, "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that Liberty Biopharma may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to Liberty Biopharma. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and Liberty Biopharma is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
For further information, please contact:
Liberty Biopharma Inc.
Alan Tam, CPA, CA
Chief Financial Officer
Telephone: (604) 604-377-7575
We just sent you an email. Please click the link in the email to confirm your subscription!
OKSubscriptions powered by Strikingly